The majority (60%) of medullary thyroid cancers (MTCs) are driven by mutations in the rearranged during transfection (RET) proto-oncogene, leading to inappropriate activation of growth factor signalling pathways such as the mitogen-activated protein kinase (MAPK) pathway (1). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.